Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
PSILOCYBIN, an indoleamine hallucinogen, produces a psychosis-like syndrome in humans that resembles first episodes of schizophrenia. In healthy human volunteers, the psychotomimetic effects of psilocybin were blocked dose-dependently by the serotonin-2A antagonist ketanserin or the atypical antipsy...
Gespeichert in:
| Veröffentlicht in: | Neuroreport 1998-12, Vol.9 (17), p.3897-3902 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3902 |
|---|---|
| container_issue | 17 |
| container_start_page | 3897 |
| container_title | Neuroreport |
| container_volume | 9 |
| creator | Vollenweider, Franz X Vollenweider-Scherpenhuyzen, Margreet F. I Bäbler, Andreas Vogel, Helen Hell, Daniel |
| description | PSILOCYBIN, an indoleamine hallucinogen, produces a psychosis-like syndrome in humans that resembles first episodes of schizophrenia. In healthy human volunteers, the psychotomimetic effects of psilocybin were blocked dose-dependently by the serotonin-2A antagonist ketanserin or the atypical antipsychotic risperidone, but were increased by the dopamine antagonist and typical antipsychotic haloperidol. These data are consistent with animal studies and provide the first evidence in humans that psilocybin-induced psychosis is due to serotonin-2A receptor activation, independently of dopamine stimulation. Thus, serotonin-2A overactivity may be involved in the pathophysiology of schizophrenia and serotonin-2A antagonism may contribute to therapeutic effects of antipsychotics. |
| doi_str_mv | 10.1097/00001756-199812010-00024 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17161690</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17161690</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4814-a47a5a32019497141eacf7b6c5beb4109bd947fbc08d06a56c26d6ee1ca568c43</originalsourceid><addsrcrecordid>eNp1kU1v1DAQQC0EKtvCT0DyAXEz2Ik_4iOqKCBVgkORql6sieMQ06y9eBKq5ddjuks51RePPG9mNM-EUMHfCm7NO16PMEozYW0nGi44qy-NfEI2QpqWKdVdPyUbbpVl0mr1nJwi_qiI5aI7ISe2M8o0akNuvmKcs9_3MdGYhtUHpOin-DvvphJSBDbH20B3uPdTxogVotO6hYT0VwQKFEPJS04xsYbC9xrgQsEvMacX5NkIM4aXx_uMfLv4cHX-iV1--fj5_P0l87ITkoE0oKCtO1hpjZAigB9Nr73qQy_rtv1gpRl7z7uBa1DaN3rQIQhf487L9oy8OfTdlfxzDbi4bUQf5hlSyCs6YYQW2vIKdgfQl4xYwuh2JW6h7J3g7q9W90-re9Dq7rXW0lfHGWu_DcND4dFjzb8-5gE9zGOB5CP-72-0anhbMXnA7vK8hIK383oXipsCzMvkHvvU9g_A85A7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17161690</pqid></control><display><type>article</type><title>Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Vollenweider, Franz X ; Vollenweider-Scherpenhuyzen, Margreet F. I ; Bäbler, Andreas ; Vogel, Helen ; Hell, Daniel</creator><creatorcontrib>Vollenweider, Franz X ; Vollenweider-Scherpenhuyzen, Margreet F. I ; Bäbler, Andreas ; Vogel, Helen ; Hell, Daniel</creatorcontrib><description>PSILOCYBIN, an indoleamine hallucinogen, produces a psychosis-like syndrome in humans that resembles first episodes of schizophrenia. In healthy human volunteers, the psychotomimetic effects of psilocybin were blocked dose-dependently by the serotonin-2A antagonist ketanserin or the atypical antipsychotic risperidone, but were increased by the dopamine antagonist and typical antipsychotic haloperidol. These data are consistent with animal studies and provide the first evidence in humans that psilocybin-induced psychosis is due to serotonin-2A receptor activation, independently of dopamine stimulation. Thus, serotonin-2A overactivity may be involved in the pathophysiology of schizophrenia and serotonin-2A antagonism may contribute to therapeutic effects of antipsychotics.</description><identifier>ISSN: 0959-4965</identifier><identifier>EISSN: 1473-558X</identifier><identifier>DOI: 10.1097/00001756-199812010-00024</identifier><identifier>PMID: 9875725</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins, Inc</publisher><subject>Adult ; Adult and adolescent clinical studies ; Analysis of Variance ; Biological and medical sciences ; Dose-Response Relationship, Drug ; Female ; Hallucinogens - adverse effects ; Humans ; Ketanserin - pharmacology ; Male ; Medical sciences ; Neuropsychological Tests ; Psilocybin - adverse effects ; Psychology. Psychoanalysis. Psychiatry ; Psychomotor Performance - drug effects ; Psychopathology. Psychiatry ; Psychoses ; Reaction Time - drug effects ; Reference Values ; Schizophrenia ; Schizophrenia - chemically induced ; Serotonin Antagonists - pharmacology ; Serotonin Receptor Agonists - adverse effects</subject><ispartof>Neuroreport, 1998-12, Vol.9 (17), p.3897-3902</ispartof><rights>1998 Lippincott Williams & Wilkins, Inc.</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4814-a47a5a32019497141eacf7b6c5beb4109bd947fbc08d06a56c26d6ee1ca568c43</citedby><cites>FETCH-LOGICAL-c4814-a47a5a32019497141eacf7b6c5beb4109bd947fbc08d06a56c26d6ee1ca568c43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1765203$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9875725$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vollenweider, Franz X</creatorcontrib><creatorcontrib>Vollenweider-Scherpenhuyzen, Margreet F. I</creatorcontrib><creatorcontrib>Bäbler, Andreas</creatorcontrib><creatorcontrib>Vogel, Helen</creatorcontrib><creatorcontrib>Hell, Daniel</creatorcontrib><title>Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action</title><title>Neuroreport</title><addtitle>Neuroreport</addtitle><description>PSILOCYBIN, an indoleamine hallucinogen, produces a psychosis-like syndrome in humans that resembles first episodes of schizophrenia. In healthy human volunteers, the psychotomimetic effects of psilocybin were blocked dose-dependently by the serotonin-2A antagonist ketanserin or the atypical antipsychotic risperidone, but were increased by the dopamine antagonist and typical antipsychotic haloperidol. These data are consistent with animal studies and provide the first evidence in humans that psilocybin-induced psychosis is due to serotonin-2A receptor activation, independently of dopamine stimulation. Thus, serotonin-2A overactivity may be involved in the pathophysiology of schizophrenia and serotonin-2A antagonism may contribute to therapeutic effects of antipsychotics.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Analysis of Variance</subject><subject>Biological and medical sciences</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Hallucinogens - adverse effects</subject><subject>Humans</subject><subject>Ketanserin - pharmacology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropsychological Tests</subject><subject>Psilocybin - adverse effects</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychomotor Performance - drug effects</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychoses</subject><subject>Reaction Time - drug effects</subject><subject>Reference Values</subject><subject>Schizophrenia</subject><subject>Schizophrenia - chemically induced</subject><subject>Serotonin Antagonists - pharmacology</subject><subject>Serotonin Receptor Agonists - adverse effects</subject><issn>0959-4965</issn><issn>1473-558X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1v1DAQQC0EKtvCT0DyAXEz2Ik_4iOqKCBVgkORql6sieMQ06y9eBKq5ddjuks51RePPG9mNM-EUMHfCm7NO16PMEozYW0nGi44qy-NfEI2QpqWKdVdPyUbbpVl0mr1nJwi_qiI5aI7ISe2M8o0akNuvmKcs9_3MdGYhtUHpOin-DvvphJSBDbH20B3uPdTxogVotO6hYT0VwQKFEPJS04xsYbC9xrgQsEvMacX5NkIM4aXx_uMfLv4cHX-iV1--fj5_P0l87ITkoE0oKCtO1hpjZAigB9Nr73qQy_rtv1gpRl7z7uBa1DaN3rQIQhf487L9oy8OfTdlfxzDbi4bUQf5hlSyCs6YYQW2vIKdgfQl4xYwuh2JW6h7J3g7q9W90-re9Dq7rXW0lfHGWu_DcND4dFjzb8-5gE9zGOB5CP-72-0anhbMXnA7vK8hIK383oXipsCzMvkHvvU9g_A85A7</recordid><startdate>19981201</startdate><enddate>19981201</enddate><creator>Vollenweider, Franz X</creator><creator>Vollenweider-Scherpenhuyzen, Margreet F. I</creator><creator>Bäbler, Andreas</creator><creator>Vogel, Helen</creator><creator>Hell, Daniel</creator><general>Lippincott Williams & Wilkins, Inc</general><general>Lippincott Williams and Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>19981201</creationdate><title>Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action</title><author>Vollenweider, Franz X ; Vollenweider-Scherpenhuyzen, Margreet F. I ; Bäbler, Andreas ; Vogel, Helen ; Hell, Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4814-a47a5a32019497141eacf7b6c5beb4109bd947fbc08d06a56c26d6ee1ca568c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Analysis of Variance</topic><topic>Biological and medical sciences</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Hallucinogens - adverse effects</topic><topic>Humans</topic><topic>Ketanserin - pharmacology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropsychological Tests</topic><topic>Psilocybin - adverse effects</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychomotor Performance - drug effects</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychoses</topic><topic>Reaction Time - drug effects</topic><topic>Reference Values</topic><topic>Schizophrenia</topic><topic>Schizophrenia - chemically induced</topic><topic>Serotonin Antagonists - pharmacology</topic><topic>Serotonin Receptor Agonists - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vollenweider, Franz X</creatorcontrib><creatorcontrib>Vollenweider-Scherpenhuyzen, Margreet F. I</creatorcontrib><creatorcontrib>Bäbler, Andreas</creatorcontrib><creatorcontrib>Vogel, Helen</creatorcontrib><creatorcontrib>Hell, Daniel</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Neuroreport</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vollenweider, Franz X</au><au>Vollenweider-Scherpenhuyzen, Margreet F. I</au><au>Bäbler, Andreas</au><au>Vogel, Helen</au><au>Hell, Daniel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action</atitle><jtitle>Neuroreport</jtitle><addtitle>Neuroreport</addtitle><date>1998-12-01</date><risdate>1998</risdate><volume>9</volume><issue>17</issue><spage>3897</spage><epage>3902</epage><pages>3897-3902</pages><issn>0959-4965</issn><eissn>1473-558X</eissn><abstract>PSILOCYBIN, an indoleamine hallucinogen, produces a psychosis-like syndrome in humans that resembles first episodes of schizophrenia. In healthy human volunteers, the psychotomimetic effects of psilocybin were blocked dose-dependently by the serotonin-2A antagonist ketanserin or the atypical antipsychotic risperidone, but were increased by the dopamine antagonist and typical antipsychotic haloperidol. These data are consistent with animal studies and provide the first evidence in humans that psilocybin-induced psychosis is due to serotonin-2A receptor activation, independently of dopamine stimulation. Thus, serotonin-2A overactivity may be involved in the pathophysiology of schizophrenia and serotonin-2A antagonism may contribute to therapeutic effects of antipsychotics.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>9875725</pmid><doi>10.1097/00001756-199812010-00024</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-4965 |
| ispartof | Neuroreport, 1998-12, Vol.9 (17), p.3897-3902 |
| issn | 0959-4965 1473-558X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17161690 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Adult and adolescent clinical studies Analysis of Variance Biological and medical sciences Dose-Response Relationship, Drug Female Hallucinogens - adverse effects Humans Ketanserin - pharmacology Male Medical sciences Neuropsychological Tests Psilocybin - adverse effects Psychology. Psychoanalysis. Psychiatry Psychomotor Performance - drug effects Psychopathology. Psychiatry Psychoses Reaction Time - drug effects Reference Values Schizophrenia Schizophrenia - chemically induced Serotonin Antagonists - pharmacology Serotonin Receptor Agonists - adverse effects |
| title | Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T15%3A08%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psilocybin%20induces%20schizophrenia-like%20psychosis%20in%20humans%20via%20a%20serotonin-2%20agonist%20action&rft.jtitle=Neuroreport&rft.au=Vollenweider,%20Franz%20X&rft.date=1998-12-01&rft.volume=9&rft.issue=17&rft.spage=3897&rft.epage=3902&rft.pages=3897-3902&rft.issn=0959-4965&rft.eissn=1473-558X&rft_id=info:doi/10.1097/00001756-199812010-00024&rft_dat=%3Cproquest_cross%3E17161690%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17161690&rft_id=info:pmid/9875725&rfr_iscdi=true |